AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

Oncolytics Biotech (TSX:ONC), a clinical-stage cancer therapy company, announced a US$20 million share purchase agreement ...

On The Readout LOUD podcast, STAT reporters talked with BIO's CEO John Crowley about RFK Jr. and tariffs, and discussed calls ...

For those of us who consume too much processed food in our diet, which are often low in fiber or lacking fiber entirely, ...

The future of food security is increasingly threatened by the aggressive patenting strategies of major biotech corporations, ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

VC execs write to Sen. Cassidy about FDA staffing concerns, citing delays & uncertainties due to loss of experienced staff & ...

The biopharmaceutical company has announced the receipt of final approval from the United States Food and Drug Administration (USFDA) for marketing its Teriflunomide Tablets in various strengths.

The uptick in Concord Biotech share price came after the company was granted final approval from the USFDA for marketing its ...

Vodafone Idea, NTPC, Concord Biotech, HAL, IRB Infrastructure, NTPC Green Energy and BPCL will be in the spotlight on ...